Newsroom
Sorted by: Latest
-
Samenvatting: IQM steunt NVIDIA’s werk om kwantumcomputers inplanbaar te maken in Slurm
CHICAGO--(BUSINESS WIRE)--IQM Quantum Computers (Nasdaq: IQMX), een internationale leider in supergeleidende kwantumcomputers, maakte vandaag op SC26 in Chicago zijn steun bekend voor NVIDIA’s investering om van QPU's (Quantum Processing Units) een inplanbare bron in de Slurm workloadmanager te maken door IQM kwantumcomputers te integreren. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in d...
-
Riassunto: IQM supporta le attività di NVIDIA per rendere i computer quantistici programmabili in Slurm
CHICAGO--(BUSINESS WIRE)--IQM Quantum Computers (Nasdaq: IQMX), un leader globale nei computer quantistici superconduttori, oggi ha annunciato al SC26 di Chicago il suo supporto per l'investimento di NVIDIA nel rendere le unità di elaborazione quantistica (QPU) una risorsa programmabile nel manager dei flussi di lavoro Slurm integrando computer quantistici IQM. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono off...
-
Resumen: Argenta y Loyal anuncian una colaboración estratégica para impulsar LOY-003, el candidato de Loyal para prolongar la esperanza de vida de los perros de razas grandes
SHAWNEE, Kansas, y SAN FRANCISCO--(BUSINESS WIRE)--Argenta, organización global de desarrollo, investigación y fabricación por contrato especializada exclusivamente en salud animal (CDRMO), y Loyal, empresa del sector de la salud animal en fase clínica que desarrolla los primeros fármacos destinados a prolongar la esperanza de vida de los perros, anunciaron hoy una colaboración estratégica. En virtud de este acuerdo, Argenta respaldará las primeras fases de desarrollo de LOY-003, el candidato e...
-
Argenta und Loyal geben Partnerschaft zur Weiterentwicklung von LOY-003 bekannt, dem Wirkstoffkandidaten von Loyal zur Verlängerung der Lebensdauer von Hunden großer Rassen
SHAWNEE, Kansas & SAN FRANCISCO--(BUSINESS WIRE)--Argenta, ein weltweit tätiges Auftragsentwicklungs-, Forschungs- und Produktionsunternehmen (CDRMO), das sich ausschließlich auf die Tiergesundheit spezialisiert hat, und Loyal, ein Tiergesundheitsunternehmen im klinischen Stadium, das Pionierarbeit bei den ersten Lebensdauerverlängerungsmedikamenten für Hunde leistet, gaben heute eine strategische Partnerschaft bekannt, in deren Rahmen Argenta die frühe Entwicklungsphase von LOY-003 unterstütze...
-
Riassunto: Argenta e Loyal annunciano una collaborazione per lo sviluppo di LOY-003, il candidato farmaco di Loyal per prolungare la vita dei cani di grossa taglia
SHAWNEE, Kan. e SAN FRANCISCO--(BUSINESS WIRE)--Argenta, l'organizzazione globale di ricerca, sviluppo e produzione a contratto (CDRMO) dedicata esclusivamente alla salute degli animali, e Loyal, l'azienda di fase clinica specializzata nella salute degli animali, pioniera dei primi farmaci in grado di estendere la vita dei cani, oggi hanno annunciato una collaborazione strategica che vedrà Argenta fornire supporto allo sviluppo nelle fasi iniziali di LOY-003, il candidato farmaco sperimentale d...
-
Argenta et Loyal annoncent un partenariat destiné à faire progresser le LOY-003, candidat-médicament de Loyal visant à prolonger la durée de vie des chiens de grande race
SHAWNEE, Kansas et SAN FRANCISCO--(BUSINESS WIRE)--Argenta, organisation mondiale de développement, de recherche et de fabrication sous contrat (CDRMO) dédiée exclusivement à la santé animale, et Loyal, entreprise de santé animale au stade clinique, qui innove en développant les premiers médicaments destinés à prolonger la durée de vie des chiens, ont annoncé aujourd'hui un partenariat stratégique. Dans ce cadre, Argenta accompagnera les premières étapes du développement de LOY-003, un candidat...
-
Samenvatting: Argenta en Loyal kondigen samenwerking aan om LOY-003, het kandidaat-geneesmiddel van Loyal voor het verlengen van de levensduur van grote hondenrassen, verder te ontwikkelen
SHAWNEE, Kan. & SAN FRANCISCO--(BUSINESS WIRE)--Argenta, de wereldwijde organisatie voor contractontwikkeling, onderzoek en productie (CDRMO) die zich uitsluitend richt op diergeneeskunde, en Loyal, het diergeneeskundige bedrijf in de klinische fase dat baanbrekend werk verricht op het gebied van de eerste geneesmiddelen voor levensverlenging bij honden, hebben vandaag een strategisch partnerschap aangekondigd. In het kader hiervan zal Argenta de vroege ontwikkelingsfase van LOY-003 ondersteune...
-
U.S. Food and Drug Administration Approves FoundationOne®Liquid CDx as the First Companion Diagnostic in the U.S. for WILSERDLY (giredestrant) in Combination with Everolimus for ER-Positive, HER2-Negative, ESR1-Mutated Advanced Breast Cancer
BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®Liquid CDx to be used as a companion diagnostic (CDx) for WILSERDLY (giredestrant) in combination with everolimus. FoundationOne Liquid CDx is the first FDA-approved companion diagnostic to identify patients who may be eligible for WILSERDLY in combination with everolimus and is...
-
MediaCo Reports Third Quarter Financial Results
NEW YORK--(BUSINESS WIRE)--MediaCo Holding Inc. (Nasdaq: MDIA) reported financial results for the third quarter ended September 30, 2026. Year-to-date Net Revenue was $94.0 million, down $0.7 million, or 1%, from the prior year, driven primarily by a decrease in spot revenue, partially offset by new digital revenue sales. Year-to-date Net Loss was $27.3 million, compared to a Net Loss of $33.9 million from the prior year, primarily due to a decrease in music licensing, rent, utilities, non-cash...
-
AYTU Stock Alert: Halper Sadeh LLC is Investigating Whether Aytu BioPharma, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Aytu BioPharma, Inc. (NASDAQ: AYTU) to Rosemont Pharmaceuticals Holdings, Inc. for $2.70 per share.Halper Sadeh encourages Aytu shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.The investigation concerns whether Aytu and its board of directors vio...